Study of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide

Completed

• Conditions: Type 2 Diabetes Mellitus

• Registration Number: NCT02201550
• Lead Sponsor: Hvidovre University Hospital

Brief Summary

The purpose of this study is to determine the effect of exogenous glucagon-like peptide-1 on the immune system i.e on the regulation of immune cells important in diseases such as obesity and diabetes.

The hypotheses are:

* Glucagon-like peptide-1 has an immunological effect observed by studying immune cells in the blood

* Treatment with glucagon-like peptide-1 increases the number of immune cells in the blood

* Treatment with glucagon-like peptide-1 leads to a more anti-inflammatory cytokine profile in the blood

Detailed Description

Not available

Study Timeline

• Study Start: 2013-02
• Primary Completion: 2014-04
• Study Completion: 2014-04
• Status Verified: 2014-07
• Study First Submitted: 2014-07-24
• Study First Submitted QC: 2014-07-24
• Last Update Submitted: 2014-07-24
• Study First Posted: 2014-07-28
• Last Update Posted: 2014-07-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 9

Inclusion Criteria

• Type 2 diabetes
• BMI > 27 kg/m2
• Planed start of treatment with liraglutide
• Age > 18 years

Exclusion Criteria

• Infection or active inflammatory disorder
• Immunomodulating treatment (i.e nonsteroidal antiinflammatory drugs, glucocorticoids)
• Smoking
• Alcohol consumption > 14 beverages/week
• Former bariatric surgery

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in number of specific immune cells in blood detected by flow cytometry	Before and 12 weeks after initiation of liraglutide treatment

Trial Locations

Locations (1)

Hvidovre University Hospital; 🇩🇰 Hvidovre, Denmark